Terms: = Head and neck cancer AND CTLA4, ALPS5, CD, CD152, CELIAC3, CTLA-4, GRD4, GSE, IDDM12 AND Treatment
378 results:
1. Enhanced ctla-4 blockade anti-tumor immunity with APG-157 combination in a murine head and neck cancer.
Shin DS; Basak S; Veena MS; Comin-Anduix B; Bhattacharya A; Dong TS; Ko A; Han P; Jacobs J; Moatamed NA; Avila L; Pellegrini M; Wang M; Srivatsan ES
Cancer Med; 2024 May; 13(9):e7212. PubMed ID: 38686626
[TBL] [Abstract] [Full Text] [Related]
2. The influence of postoperative outcomes on survival after esophageal cancer surgery: validation of a consensus-based updated textbook outcome parameter.
D'Souza J; Cinelli DP; McCombie A; Roberts R
J Gastrointest Surg; 2024 Apr; 28(4):343-350. PubMed ID: 38583882
[TBL] [Abstract] [Full Text] [Related]
3. Single-cell profiling of response to neoadjuvant chemo-immunotherapy in surgically resectable esophageal squamous cell carcinoma.
Ji G; Yang Q; Wang S; Yan X; Ou Q; Gong L; Zhao J; Zhou Y; Tian F; Lei J; Mu X; Wang J; Wang T; Wang X; Sun J; Zhang J; Jia C; Jiang T; Zhao MG; Lu Q
Genome Med; 2024 Apr; 16(1):49. PubMed ID: 38566201
[TBL] [Abstract] [Full Text] [Related]
4. M6A-mediated molecular patterns and tumor microenvironment infiltration characterization in nasopharyngeal carcinoma.
Wang Y; Peng L; Wang F
Cancer Biol Ther; 2024 Dec; 25(1):2333590. PubMed ID: 38532632
[TBL] [Abstract] [Full Text] [Related]
5. Prognostic model revealing pyroptosis-related signatures in oral squamous cell carcinoma based on bioinformatics analysis.
Qi L; Tang Z
Sci Rep; 2024 Mar; 14(1):6149. PubMed ID: 38480853
[TBL] [Abstract] [Full Text] [Related]
6. Dual checkpoint T(h1)eamwork makes the anti-cancer dream work.
Dietl A; Ralser A; Pelka K
Immunity; 2024 Mar; 57(3):406-408. PubMed ID: 38479356
[TBL] [Abstract] [Full Text] [Related]
7. The Use of Immune Regulation in Treating head and neck Squamous Cell Carcinoma (HNSCC).
Wang CW; Biswas PK; Islam A; Chen MK; Chueh PJ
Cells; 2024 Feb; 13(5):. PubMed ID: 38474377
[TBL] [Abstract] [Full Text] [Related]
8. CD4
Franken A; Bila M; Mechels A; Kint S; Van Dessel J; Pomella V; Vanuytven S; Philips G; Bricard O; Xiong J; Boeckx B; Hatse S; Van Brussel T; Schepers R; Van Aerde C; Geurs S; Vandecaveye V; Hauben E; Vander Poorten V; Verbandt S; Vandereyken K; Qian J; Tejpar S; Voet T; Clement PM; Lambrechts D
Immunity; 2024 Mar; 57(3):541-558.e7. PubMed ID: 38442708
[TBL] [Abstract] [Full Text] [Related]
9. Efficacy and safety of cadonilimab in previously treated recurrent or metastatic nasopharyngeal carcinoma(COMPASSION-06): A phase II multicenter study.
Chen QY; Guo SS; Luo Y; Qu S; Wu DH; Chen XZ; Chen DP; Qin XT; Lin Q; Jin F; Lin SJ; Yao ZF; Liu W; Maxwell Wang Z; Li BY; Xia M; Xu RH; Tang LQ; Mai HQ
Oral Oncol; 2024 Apr; 151():106723. PubMed ID: 38387261
[TBL] [Abstract] [Full Text] [Related]
10. Tumor histoculture captures the dynamic interactions between tumor and immune components in response to anti-PD1 in head and neck cancer.
Basak NP; Jaganathan K; Das B; Muthusamy O; M R; Malhotra R; Samal A; Nath M; Ms G; Shankar AP; Bv P; Pillai V; Bv M; C J; K V; K GS; Govindan S; V S; Juby ; R K; Bhowal C; Kumar U; K G; Malhotra M; Sankaran S
Nat Commun; 2024 Feb; 15(1):1585. PubMed ID: 38383563
[TBL] [Abstract] [Full Text] [Related]
11. INDUCE-2: A Phase I/II, open-label, two-part study of feladilimab in combination with tremelimumab in patients with advanced solid tumors.
Hilton JF; Ott PA; Hansen AR; Li Z; Mathew M; Messina CH; Dave V; Ji X; Karpinich NO; Hirschfeld S; Ballas M; Zandberg DP
Cancer Immunol Immunother; 2024 Feb; 73(3):44. PubMed ID: 38349570
[TBL] [Abstract] [Full Text] [Related]
12. Different patient versus provider perspectives on living with Cushing's disease.
Halstrom A; Lin IH; Lin A; Cohen M; Tabar V; Geer EB
Pituitary; 2024 Apr; 27(2):141-150. PubMed ID: 38315244
[TBL] [Abstract] [Full Text] [Related]
13. Immunotherapy for non-small cell lung cancer.
Kagamu H
Respir Investig; 2024 Mar; 62(2):307-312. PubMed ID: 38310751
[TBL] [Abstract] [Full Text] [Related]
14. Clear cell oral squamous cell carcinoma as a diagnostic conundrum: report of 2 rare cases.
Sharma K; Chauhan A; Sharma P; Wadhwan V; Tyagi S; Sharma R
Oral Surg Oral Med Oral Pathol Oral Radiol; 2024 May; 137(5):e83-e90. PubMed ID: 38281881
[TBL] [Abstract] [Full Text] [Related]
15. Development and validation of glycosyltransferase related-gene for the diagnosis and prognosis of head and neck squamous cell carcinoma.
He M; Wang L; Yue Z; Feng C; Dai G; Jiang J; Huang H; Ji Q; Zhou M; Li D; Chai W
Aging (Albany NY); 2024 Jan; 16(2):1750-1766. PubMed ID: 38244579
[TBL] [Abstract] [Full Text] [Related]
16. Evaluation of photobiomodulation therapy (PBMT) on salivary flow and composition in head and neck cancer patients undergoing radiation therapy.
Schepanski N; Costa FS; Machado EFM; Pacheco MN; Amaral CDB; Machado RC; Nogueira ARA; Brancher JA; Sassi LM; de Araujo MR
Oral Surg Oral Med Oral Pathol Oral Radiol; 2024 Mar; 137(3):253-263. PubMed ID: 38218654
[TBL] [Abstract] [Full Text] [Related]
17. The dynamic role of immune checkpoint molecules in diagnosis, prognosis, and treatment of head and neck cancers.
Mestiri S; El-Ella DMA; Fernandes Q; Bedhiafi T; Almoghrabi S; Akbar S; Inchakalody V; Assami L; Anwar S; Uddin S; Gul ARZ; Al-Muftah M; Merhi M; Raza A; Dermime S
Biomed Pharmacother; 2024 Feb; 171():116095. PubMed ID: 38183744
[TBL] [Abstract] [Full Text] [Related]
18. Immune checkpoint inhibitors and cancer immunotherapy by aptamers: an overview.
Kejamurthy P; Devi KTR
Med Oncol; 2023 Dec; 41(1):40. PubMed ID: 38158454
[TBL] [Abstract] [Full Text] [Related]
19. Tumour microenvironment influences response to treatment in oesophageal adenocarcinoma.
Belle CJ; Lonie JM; Brosda S; Barbour AP
Front Immunol; 2023; 14():1330635. PubMed ID: 38155973
[TBL] [Abstract] [Full Text] [Related]
20. Immunotherapy for Unresectable Small Bowel Adenocarcinoma: A Case Series.
Sugiyama K; Owaki S; Sato M; Shiraishi K; Kato K; Kitagawa C
In Vivo; 2024; 38(1):518-522. PubMed ID: 38148069
[TBL] [Abstract] [Full Text] [Related]
[Next]
